However, there was no significant association between RE neoantigen burden and somatic neoantigen burden in different cancers except in bladder urothelial carcinoma (BLCA), nor was there a correlation with expression of the immune markers including CD8A, GZMA, PD1, or clinical covariates except for the age in breast invasive carcinoma (BRCA) (Benjamini and Hochberg adjusted P > 0.05 for all) (Figure 2E, Table S7A). This evidence concerns the gene GZMA and bladder transitional cell carcinoma.